Corvus Pharmaceuticals announces Phase 1b trial of soquelitinib for hidradenitis suppurativa
CRVS•Corvus Pharmaceuticals initiated a Phase 1b clinical trial of soquelitinib in patients with hidradenitis suppurativa. The primary endpoint is safety and tolerability; key efficacy endpoints are HiSCR 50/75 at week 12.
1. Trial endpoints
Corvus Pharmaceuticals said it initiated a Phase 1b clinical trial of soquelitinib for patients with hidradenitis suppurativa. The primary endpoint is safety and tolerability, and key efficacy endpoints are HiSCR 50/75 at week 12.
